Skip to content

Celestial Therapeutics

6 viewers · 30d

Total raised

$850K

8 filings since 2024 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $850K
ROUNDS
8
INVESTORS
5
FOUNDED
N/A
HQ
Irvine, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Celestial Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies aimed at treating, preventing, and curing infectious diseases, inflammatory conditions, and various forms of cancer. With a strong focus on addressing key unmet medical needs, the company integrates cutting-edge technology into its therapeutic solutions.

What sets it apart

Celestial Therapeutics distinguishes itself by leveraging a proprietary self-adjuvanting mRNA vaccine platform that enhances immunogenicity while minimizing side effects.

Funding history

8 rounds
EquityApr 21, 2025 · $20K min
Form D/A
+$575K$850K total
EquityApr 21, 2025 · $20K min
Form D/A
+$625K$850K total
EquitySep 3, 2024 · $20K min
Form D/A
+$800K$850K total
EquitySep 3, 2024 · $20K min
Form D/A
+$500K$850K total
EquitySep 3, 2024 · $20K min
Form D/A
+$850K$850K total
EquitySep 3, 2024 · $20K min
Form D/A
+$550K— total
EquitySep 3, 2024 · $20K min
Form D/A
+$725K— total
EquitySep 3, 2024 · $20K min
Form D/A
+$775K— total

Products

1 tracked

CT-02

Therapeutics

CT-02 is a first-in-class broad-spectrum anti-infective and anti-inflammatory drug primarily developed for the treatment of respiratory syncytial virus (RSV). It represents a significant advancement in the realm of infectious disease management by providing effective treatment options for viral infections.

  • Broad-spectrum activity against multiple pathogens
  • Dual action as anti-infective and anti-inflammatory
  • Targeted initially at respiratory viral infections

Links

WebsiteSEC EDGAR filings